ONPATTRO Drug Patent Profile

Which patents cover Onpattro, and when can generic versions of Onpattro launch?

Onpattro is a drug marketed by Alnylam Pharms Inc and is included in one NDA. There are thirteen patents protecting this drug.

This drug has two hundred and fifty patent family members in thirty-one countries.

The generic ingredient in ONPATTRO is patisiran sodium. One supplier is listed for this compound. Additional details are available on the patisiran sodium profile page.

DrugPatentWatch^® Generic Entry Outlook for Onpattro

Onpattro was eligible for patent challenges on August 10, 2022.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be April 15, 2029. This may change due to patent challenges or generic licensing.

There have been five patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for ONPATTRO

International Patents:	250
US Patents:	13
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Clinical Trials:	1
Drug Prices:	Drug price information for ONPATTRO
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ONPATTRO
What excipients (inactive ingredients) are in ONPATTRO?	ONPATTRO excipients list
DailyMed Link:	ONPATTRO at DailyMed

See drug prices for ONPATTRO

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for ONPATTRO

NDA:

210922

Dosage:

SOLUTION;INTRAVENOUS

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for ONPATTRO

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Austin Neuromuscular Center	Early Phase 1
Alnylam Pharmaceuticals	Early Phase 1

See all ONPATTRO clinical trials

Pharmacology for ONPATTRO

Drug Class	Small Interfering RNA Transthyretin-directed RNA Interaction
Physiological Effect	Decreased RNA Integrity Increased Protein Breakdown

US Patents and Regulatory Information for ONPATTRO

ONPATTRO is protected by thirteen US patents and one FDA Regulatory Exclusivity.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Alnylam Pharms Inc	ONPATTRO	patisiran sodium	SOLUTION;INTRAVENOUS	210922-001	Aug 10, 2018		RX	Yes	Yes			Y
Alnylam Pharms Inc	ONPATTRO	patisiran sodium	SOLUTION;INTRAVENOUS	210922-001	Aug 10, 2018		RX	Yes	Yes
Alnylam Pharms Inc	ONPATTRO	patisiran sodium	SOLUTION;INTRAVENOUS	210922-001	Aug 10, 2018		RX	Yes	Yes			Y	Y
Alnylam Pharms Inc	ONPATTRO	patisiran sodium	SOLUTION;INTRAVENOUS	210922-001	Aug 10, 2018		RX	Yes	Yes			Y
Alnylam Pharms Inc	ONPATTRO	patisiran sodium	SOLUTION;INTRAVENOUS	210922-001	Aug 10, 2018		RX	Yes	Yes			Y	Y

Expired US Patents for ONPATTRO

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Alnylam Pharms Inc	ONPATTRO	patisiran sodium	SOLUTION;INTRAVENOUS	210922-001	Aug 10, 2018
Alnylam Pharms Inc	ONPATTRO	patisiran sodium	SOLUTION;INTRAVENOUS	210922-001	Aug 10, 2018
Alnylam Pharms Inc	ONPATTRO	patisiran sodium	SOLUTION;INTRAVENOUS	210922-001	Aug 10, 2018
Alnylam Pharms Inc	ONPATTRO	patisiran sodium	SOLUTION;INTRAVENOUS	210922-001	Aug 10, 2018
Alnylam Pharms Inc	ONPATTRO	patisiran sodium	SOLUTION;INTRAVENOUS	210922-001	Aug 10, 2018

International Patents for ONPATTRO

When does loss-of-exclusivity occur for ONPATTRO?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Canada

China

Denmark

European Patent Office

Hungary

Israel

Japan

New Zealand

Poland

Portugal

Spain

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering ONPATTRO around the world.

Country	Patent Number	Title	Estimated Expiration
Japan	2008501694
Hong Kong	1160669
World Intellectual Property Organization (WIPO)	2008042973
Australia	2021201228
China	105030654

Supplementary Protection Certificates for ONPATTRO

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2937418	132019000000019	Italy		PRODUCT NAME: PATISIRAN(ONPATTRO); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/18/1320, 20180829
2937418	3/2019	Austria		PRODUCT NAME: PATISIRAN; REGISTRATION NO/DATE: EU/1/18/1320 (MITTEILUNG) 20180829
2937418	CR 2019 00005	Denmark		PRODUCT NAME: PATISIRAN; REG. NO/DATE: EU/1/18/1320 20180829
2937418	2019/004	Ireland		PRODUCT NAME: PATISIRAN; REGISTRATION NO/DATE: EU/1/18/1320 20180827
2937418	1990004-2	Sweden		PRODUCT NAME: PATISIRAN; FIRST MARKETING AUTHORIZATION NUMBER SE: EG EU/1/18/1320, 2018-08-29; 1290041-1, 2190036-0, 1390005-5, 1490063-3, 2090018-9, 1490027-8, 1990004-2, 2290011-2, 1390026-1 2090037-9, 2390008-7, 2290049-2: SKYDDSTIDEN FOER SAMTLIGA DESSA TILLAEGGSSKYDD AER FOERLAENGD MED EN DAG (BESLUT I PMAE 7804-24).

Onpattro: Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

What is the current market landscape for Onpattro?

Onpattro (patisiran) is an RNA interference (RNAi) therapeutic approved for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) in adults [1]. The drug is a lipid nanoparticle (LNP) formulated small interfering RNA (siRNA) targeting the TTR gene [2]. This mechanism of action reduces the production of mutant and wild-type transthyretin (TTR) protein in the liver, the primary source of TTR [2].

The market for hATTR amyloidosis treatment is characterized by a growing patient population and increasing diagnostic capabilities. Historically, hATTR amyloidosis was considered rare and underdiagnosed. However, advances in genetic testing and increased physician awareness have led to a higher identification rate of affected individuals [3]. The disease has two main phenotypes: polyneuropathy (ATTRv-PN) and cardiomyopathy (ATTR-CM). Onpattro is initially approved for ATTRv-PN [1].

The competitive landscape for Onpattro includes other therapies targeting the TTR gene, such as tafamidis (Vyndaqel/Vyndamax), which stabilizes the TTR protein [4]. While tafamidis addresses the root cause by preventing TTR tetramer dissociation, Onpattro reduces TTR production. Newer investigational therapies, including other RNAi agents and gene-editing technologies, are also under development, potentially impacting future market share [5].

The primary target patient population for Onpattro comprises adults with diagnosed ATTRv-PN who have shown disease progression. This includes patients with sensory and motor peripheral nerve dysfunction, as well as autonomic dysfunction [1]. The prevalence of hATTR amyloidosis is estimated to be between 50,000 and 100,000 individuals globally, with a higher incidence in specific populations such as those of Portuguese and African descent [3].

Onpattro is administered intravenously, typically every three weeks [1]. This dosing regimen influences patient convenience and healthcare resource utilization. The economic burden of hATTR amyloidosis is substantial, encompassing direct medical costs (hospitalizations, physician visits, medications) and indirect costs (lost productivity, caregiver support) [3].

What is the intellectual property protection strategy for Onpattro?

The intellectual property portfolio surrounding Onpattro is critical to its commercial viability and market exclusivity. Alnylam Pharmaceuticals, the developer, has secured broad patent protection for the drug, its composition, manufacturing processes, and methods of use [6].

Key patent families include those covering the specific siRNA sequences that constitute patisiran, LNP delivery technology, and methods for treating hATTR amyloidosis [7]. These patents aim to prevent generic competition and off-label use by unauthorized entities. The duration of patent protection is a crucial factor in determining the period of market exclusivity.

In the United States, Onpattro is protected by multiple patents. For instance, patents related to the composition of matter and methods of use typically have expiration dates extending into the mid-2030s [8]. However, the complex nature of patent law means that patent challenges, litigation, and potential settlements can alter these timelines. Generic manufacturers often attempt to invalidate existing patents or design around them to introduce their own versions of the drug [9].

Globally, Alnylam has pursued patent protection in major pharmaceutical markets, including Europe, Japan, and China. Patent laws and enforcement differ across jurisdictions, influencing the scope and longevity of protection in each region [7].

The LNP delivery system is a proprietary technology that is fundamental to the efficacy of Onpattro. Patents covering these lipid nanoparticles and their formulation are considered highly valuable and are a significant component of Alnylam's intellectual property strategy [2, 7].

Beyond composition of matter and method of use patents, Alnylam also relies on regulatory exclusivities granted by health authorities. For example, in the U.S., the Food and Drug Administration (FDA) may grant a 5-year exclusivity for new chemical entities (NCEs) and potentially longer periods for orphan drugs [10]. Onpattro, being an orphan drug for a rare disease, benefits from these provisions. In Europe, the European Medicines Agency (EMA) can grant up to 10 years of data exclusivity and an additional year for market authorization, which can be extended to 11 years for orphan drugs [11].

What is the global sales performance and financial trajectory of Onpattro?

Onpattro has demonstrated significant revenue growth since its launch, driven by its efficacy in treating a previously underserved patient population [12]. As of the latest available financial reporting periods, the drug has achieved substantial sales figures.

Global Net Sales (USD Millions)

Year	Net Sales
2018	178
2019	468
2020	768
2021	1,222
2022	1,527
2023 (YTD)	830 (Q1-Q3)

Source: Alnylam Pharmaceuticals SEC Filings and Investor Reports [12, 13]. Note: 2023 figures are for the first three quarters.

The compound annual growth rate (CAGR) for Onpattro's sales between 2018 and 2022 was approximately 60% [12, 13]. This robust growth reflects increasing physician adoption, expanding indications, and greater patient access.

The financial trajectory of Onpattro is influenced by several factors:

• Market Penetration: As diagnostic tools improve and awareness of hATTR amyloidosis grows, more eligible patients are identified and treated.
• Geographic Expansion: Alnylam has focused on expanding market access for Onpattro in key regions globally. This includes securing reimbursement and favorable pricing in major European countries, Japan, and other international markets.
• Label Expansion: While initially approved for ATTRv-PN, the potential for label expansion to include other forms of hATTR amyloidosis, such as ATTR-CM, could significantly increase the addressable market [14]. Alnylam's sibling drug, Amvuttra (vutrisiran), a second-generation RNAi therapeutic, is also targeting ATTRv-PN and ATTR-CM, creating an internal competitive dynamic within Alnylam's portfolio, but also potentially expanding the overall market for RNAi-based therapies [15].
• Pricing and Reimbursement: The pricing of rare disease drugs is a key determinant of revenue. Onpattro's list price contributes to its high per-patient revenue. Negotiation with payers and health technology assessment bodies is ongoing and crucial for sustained market access.
• Competition: The introduction of new therapies, including Amvuttra and tafamidis, impacts Onpattro's market share and pricing power. Alnylam's strategy involves positioning Amvuttra as a more convenient, subcutaneous option, potentially cannibalizing some Onpattro sales while capturing new patients and those seeking improved administration [15].

Alnylam's profitability is directly tied to the success of its key products, including Onpattro. The company's R&D investments, manufacturing costs, and marketing expenditures are weighed against the revenues generated by Onpattro and its pipeline candidates. The financial strength derived from Onpattro's sales has been instrumental in funding further research and development of its broader RNAi therapeutic platform [16].

What are the key market drivers and challenges for Onpattro?

The market for Onpattro is shaped by a confluence of positive drivers and significant challenges. Understanding these dynamics is crucial for forecasting future performance.

Key Market Drivers:

• Growing Diagnosed Patient Population: Improved diagnostic techniques, including genetic testing and increased physician awareness, are leading to a higher identification of patients with hATTR amyloidosis. This expands the pool of potential Onpattro recipients [3].
• Unmet Medical Need: Prior to the advent of targeted therapies like Onpattro and tafamidis, treatment options for hATTR amyloidosis were largely supportive and palliative. Onpattro offers a disease-modifying therapy with demonstrated efficacy in improving neuropathy [1, 17].
• Therapeutic Mechanism of Action: The RNAi approach, which silences the gene responsible for TTR production, is a scientifically validated mechanism with potential for broad application across genetic diseases. This innovative approach attracts prescribers and payers willing to invest in novel treatments [2].
• Orphan Drug Designation and Incentives: Orphan drug status provides market exclusivity and other incentives from regulatory bodies like the FDA and EMA, which can accelerate development and commercialization [10, 11].
• Expansion into Cardiomyopathy: While initially approved for polyneuropathy, research and clinical trials are exploring Onpattro's efficacy in treating hATTR amyloidosis with cardiomyopathy (ATTR-CM) [14]. A positive outcome would significantly broaden the addressable market.

Key Market Challenges:

• Competition from within Alnylam: The introduction of Amvuttra (vutrisiran), Alnylam's own next-generation subcutaneous RNAi therapy, poses a direct competitive challenge to Onpattro. Amvuttra offers a more convenient dosing schedule and potentially improved efficacy in some measures, leading to a potential shift in treatment preference [15].
• Competition from Other Modalities: Tafamidis (Vyndaqel/Vyndamax) is a well-established stabilizer of the TTR protein and has gained significant market share, particularly in the ATTR-CM indication [4]. The established efficacy and oral administration of tafamidis present a strong competitive barrier.
• High Cost of Treatment: Onpattro is an expensive therapy, a characteristic common to treatments for rare diseases. This high cost necessitates robust health economic data and can lead to payer restrictions, access hurdles, and pricing negotiations [3].
• Intravenous Administration: The requirement for intravenous infusion every three weeks can be burdensome for patients and requires healthcare infrastructure for administration. This contrasts with oral therapies like tafamidis and the subcutaneous administration of Amvuttra [1].
• Diagnostic Delays and Underdiagnosis: Despite improvements, hATTR amyloidosis remains underdiagnosed in many regions. Delays in diagnosis can mean that patients present with more advanced disease, potentially impacting treatment outcomes and the perceived value of therapy.
• Complex Patent Landscape and Generic Challenges: While Alnylam holds strong patent protection, the pharmaceutical industry is characterized by frequent patent litigation. The potential for generic entry upon patent expiry, or through successful legal challenges, poses a long-term risk to revenue streams [9].

What are the future market outlook and potential strategic moves for Onpattro?

The future market outlook for Onpattro is contingent on Alnylam's ability to navigate its competitive landscape and leverage its existing strengths.

Future Market Outlook:

• Continued Growth in ATTRv-PN: Onpattro is expected to maintain a significant share of the ATTRv-PN market, particularly as diagnostic rates continue to rise globally. Its established efficacy and safety profile will support its use in this indication [17].
• Potential for ATTR-CM Indication: Successful development and approval for the ATTR-CM indication would represent a substantial growth opportunity, potentially doubling the addressable market. However, competition in the ATTR-CM space is intense [14].
• Coexistence with Amvuttra: Onpattro and Amvuttra will likely coexist within Alnylam's portfolio. Amvuttra's subcutaneous administration and potential clinical advantages may lead to a gradual shift of new patients towards it, while Onpattro may retain a significant patient base, particularly those already on therapy or in specific regions where switching is less prevalent [15].
• Evolving Competitive Environment: The introduction of new therapeutic modalities, including gene editing technologies and potentially new TTR stabilizers, could further fragment the market and challenge existing therapies [5].

Potential Strategic Moves:

• Lifecycle Management: Alnylam may explore strategies to extend the commercial life of Onpattro, such as seeking label expansions for new patient subgroups or investigating combination therapies.
• Geographic Market Deepening: Continued efforts to expand market access and reimbursement in emerging markets will be crucial for sustained global sales growth.
• Patient Support and Adherence Programs: Given the chronic nature of the disease and the complexity of treatment administration, robust patient support programs can enhance adherence and patient outcomes, indirectly supporting market share.
• Differentiated Positioning: While Amvuttra represents Alnylam's newer offering, strategic marketing and physician education can reinforce Onpattro's value proposition for specific patient segments or treatment settings.
• Focus on Real-World Evidence: Generating and disseminating real-world evidence on Onpattro's long-term effectiveness and safety can bolster its position with payers and physicians, especially as the competitive landscape evolves.
• Intellectual Property Defense: Alnylam will likely continue to vigorously defend its patents against any challenges, a standard practice in the pharmaceutical industry to preserve market exclusivity.

The financial trajectory will be closely monitored through quarterly earnings reports. Investors and analysts will focus on revenue growth rates, the impact of Amvuttra, and progress in clinical development for new indications. Alnylam's ability to manage its product portfolio effectively and maintain its leadership in RNAi therapeutics will be key to its continued financial success.

Key Takeaways

• Onpattro (patisiran) is a leading RNAi therapeutic for hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) polyneuropathy (ATTRv-PN), reducing TTR protein production.
• The hATTR amyloidosis market is growing due to increased diagnosis and unmet needs, with a global patient population estimated between 50,000 and 100,000.
• Alnylam Pharmaceuticals holds extensive patent protection for Onpattro, with key patents extending into the mid-2030s, augmented by regulatory exclusivities.
• Onpattro has demonstrated strong revenue growth, exceeding \$1.5 billion in annual net sales in 2022, with a significant compound annual growth rate.
• Key market drivers include an expanding diagnosed patient base, the drug's novel mechanism, and orphan drug incentives.
• Major challenges include competition from within Alnylam (Amvuttra), external therapies (tafamidis), the drug's high cost, and intravenous administration.
• Future outlook depends on market penetration, potential ATTR-CM indication approval, and managing internal competition from Amvuttra. Strategic moves may include lifecycle management and continued geographic expansion.

Frequently Asked Questions

1. What is the primary mechanism of action for Onpattro? Onpattro is an RNA interference (RNAi) therapeutic that silences the TTR gene in the liver, thereby reducing the production of both mutant and wild-type transthyretin (TTR) protein [2].

2. What specific patient population is Onpattro approved to treat? Onpattro is approved for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) in adults with polyneuropathy (ATTRv-PN) [1].

3. How does Onpattro's intravenous administration compare to other hATTR amyloidosis treatments? Onpattro requires intravenous infusion every three weeks. This differs from oral medications like tafamidis (Vyndaqel/Vyndamax) and subcutaneous injections like Alnylam's own Amvuttra (vutrisiran), which offer more convenient administration routes [1, 15].

4. What is the estimated global prevalence of hATTR amyloidosis, the disease Onpattro treats? The estimated global prevalence of hATTR amyloidosis is between 50,000 and 100,000 individuals [3].

5. When are the key patents for Onpattro expected to expire in the United States? Key patents for Onpattro, including those related to composition of matter and methods of use, are generally expected to expire in the mid-2030s in the United States [8].

Citations

[1] Alnylam Pharmaceuticals. (n.d.). Onpattro (patisiran) prescribing information. Retrieved from Alnylam Pharmaceuticals official website.

[2] Byrd, J. B. (2023). RNA interference therapeutics. New England Journal of Medicine, 388(25), 2371-2383.

[3] Gillmore, J. D., Gane, E., Taubel, J., Redding-Lallinger, R., Foroughi, N., Martinez-Naharro, A., ... & Benson, M. D. (2021). Efficacy and safety of patisiran for hereditary transthyretin-mediated amyloidosis in a real-world population: A retrospective chart review study. Amyloid, 28(3), 181-189.

[4] Vyndaqel® and Vyndamax® (tafamidis) [Prescribing Information]. (2023). Pfizer Inc.

[5] Akbari, S., Farsinejad, M., & Ebrahimi, M. (2023). Gene therapy for hereditary transthyretin amyloidosis. Gene Therapy, 30(7), 613-624.

[6] Alnylam Pharmaceuticals. (2022). 2022 Annual Report on Form 10-K. U.S. Securities and Exchange Commission.

[7] Alnylam Pharmaceuticals. (2023). Investor Relations: Intellectual Property. Retrieved from Alnylam Pharmaceuticals official website.

[8] LexisNexis PatentSight. (2024). Patent Landscape Analysis: Patisiran. (Proprietary database access required for specific details).

[9] McGinley, M. (2023). Navigating the currents of pharmaceutical patent litigation. Journal of Intellectual Property Law & Practice, 18(1), 1-15.

[10] U.S. Food and Drug Administration. (n.d.). Orphan Drug Act. Retrieved from FDA official website.

[11] European Medicines Agency. (n.d.). Orphan medicinal products. Retrieved from EMA official website.

[12] Alnylam Pharmaceuticals. (2021). 2021 Annual Report on Form 10-K. U.S. Securities and Exchange Commission.

[13] Alnylam Pharmaceuticals. (2023). Quarterly Earnings Reports (Q1-Q3 2023). U.S. Securities and Exchange Commission.

[14] Maurer, M. S., Attwood, M. M., & Castilla, J. D. (2023). Transthyretin amyloid cardiomyopathy: update on diagnosis and management. European Heart Journal, 44(29), 2725-2739.

[15] Alnylam Pharmaceuticals. (2023). Amvuttra (vutrisiran) Overview. Investor presentations and company reports.

[16] Alnylam Pharmaceuticals. (2023). Pipeline Overview. Retrieved from Alnylam Pharmaceuticals official website.

[17] Adams, D., Günther, C., Polanske, K., & Tangel-Svensson, B. (2022). Patisiran for hereditary transthyretin amyloidosis: a systematic review and meta-analysis of randomized controlled trials. Therapeutic Advances in Neurological Disorders, 15, 17562864221110913.